Via xLinkBsAb platform, we apply cross-linking dependency in developing anti-TNFRSF bispecific antibodies. Several IO or TA target dependent TNFRSF agonist antibodies have entered into the IND-enabling stage.
LVGN5287
xLinkBsAb checkpoint blocker and T cell activator
Co-expression of PD-1 and CD137 on immune cells in tumors
PD-1 blockade lead to increased expression of CD137
PD-1 cross-linking dependent CD137 agonist activity
Desirable drug-like properties
LVGN5596
xLinkBsAb tumor microenvironment immune activator
B7H3 targeting highly pursued in the clinic
B7H3-dependent activation of CD40 on APCs (i.e., DCs)
Cross-presentation of tumor-derived antigens
Priming of tumor-specific T cells
Cross-linking dependent activity
Desirable drug-like properties
Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines or platform technology. Please contact us to explore collaboration opportunities.
沪公网安备 31011502015346号